iNCOVACC now available on CoWin
The nasal vaccine is priced at Rs 800 for private markets and Rs 325 for governments
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Bharat Biotech
Bharat Biotech’s iNCOVACC receives primary series and heterologous booster approval
iNCOVACC is the world’s first intra-nasal vaccine for COVID to receive approval for the primary two-dose schedule, and…
50 million doses of Covaxin set to expire early 2023
Due to lack of product demand, production stoppage of Covaxin - a two dose jab, was initiated by Bharat Biotech earlier this year,…
Bharat Biotech seeks drug regulator’s nod for Incovacc’s phase-III study in five-18 age…
Incovacc is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised spike protein
DCGI gives EUA to India’s first nasal vaccine against COVID-19
BBV154 is an intra-nasal replication-deficient chimpanzee adenovirus SARS-CoV-2 vectored vaccine
Nigeria introduces Bharat Biotech’s Rotavac vaccine for immunisation in children
Rotavirus infection causes about 50,000 child fatalities under the age of five each year in Nigeria
Bharat Biotech completes clinical development for phase-III trials and booster doses for BBV154…
Data from both phase-III human clinical trials have been submitted for approval to National Regulatory Authorities
Bharat Biotech expects regulator’s nod for intranasal COVID-19 vaccine in August
The Drug Controller General of India (DCGI) gave its nod to conduct clinical trials for Bharat Biotech’s intranasal vaccine as…
Covaxin demonstrates persistence of immunity and impact of third dose of inactivated COVID-19…
Subjects were evaluated for safety, neutralising antibody responses against variants of concern, binding antibodies against spike…
Ocugen announces positive results for COVID-19 vaccine trial for children aged two-18 years
Ocugen’s partner Bharat Biotech’s phase-II/III study of Covaxin (BBV152) in 526 children showed safety, efficacy, and superior…